Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients

Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients
Trovagene will soon begin patient recruitment for its Phase 2 clinical trial evaluating PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). The study (NCT03414034) will enroll patients at Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital, the three centers where the trial will be conducted. PCM-075 is a selective polo-like kinase 1 (PLK1) inhibitor. PLK1 is a protein whose levels are particularly high in cancer cells, which often is associated with poor outcomes. PCM-075 could help trigger the death of cancer cells by inhibiting PLK1. In mCRPC, either levels of the biomarker prostate specific antigen (PSA) continue to rise or new symptoms appear after patients are treated with hormone therapies. Metastatic cancers are those that also spread to other parts of the body. Preclinical studies have shown that PCM-075 increases the punch of Zytiga, one of the world’s leading therapies for mCRPC. Zytiga works by decreasing the levels of male hormones associated with cancer. “The synergy observed when we combined PCM-075 with abiraterone appears to work through a novel mechanism that may modulate a signaling pathway previously unknown to be associated with this combination,” Mark Erlander, Trovagene’s chief scientific officer, said in the 
Subscribe or to access all post and page content.